HPTN 094 Study Examines a Novel Way to Take Addiction Care and HIV Prevention to People Who Inject Drugs March 12, 2025
Sustained Efficacy of Long-Acting Cabotegravir for PrEP Among Cisgender Women—Findings from HPTN 084 Study July 28, 2022
HPTN Studies Inform FDA’s Approval of ViiV Healthcare’s Long-Acting Cabotegravir Injections for HIV Prevention December 21, 2021
Most advanced clinical trials testing broadly neutralizing antibody against HIV demonstrate efficacy against sensitive strains January 26, 2021
HPTN Awarded U.S. National Institutes of Health Funding to Continue Research Agenda November 30, 2020
HPTN 084 Study Demonstrates Superiority of CAB LA to Oral TDF/FTC for the Prevention of HIV November 09, 2020